Heme

Advertisement
Andrew MorenoHematology | February 7, 2025
The menin inhibitor oral agent achieved the KOMET-001 trial's primary endpoints and had a favorable benefit-risk profile.
Read More
Michael DeBaun, MD, MPHSickle Cell Disease | February 6, 2025
An expert panel's review finds SCT has often been misattributed as the direct cause of mortality in patients who have SCT.
Andrew MorenoHemophilia | February 4, 2025
A study cohort with severe disease over a median follow-up of 14 months had an annualized bleeding rate of zero.
Andrew MorenoHematology | January 30, 2025
Use is also being explored for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Andrew MorenoHematology | January 30, 2025
Clinicians can use this test to help distinguish more than 60 disease subtypes from patients' normal immune response.
Andrew MorenoThrombosis | January 29, 2025
The new agent is on the 505(b)(2) regulatory pathway and was compared with tablet-form apixaban in 60 healthy volunteers.
Kenneth Adler, MDHematology | January 28, 2025
Organization-level changes at hospitals and medical groups are needed to meaningfully address this longstanding issue.
Andrew MorenoMDS | January 24, 2025
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Melissa BadamoITP | January 24, 2025
Dapsone demonstrates efficacy and acceptable safety with low costs as treatment for pediatric ITP.
Andrew MorenoHematology | January 24, 2025
Two therapies being developed for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus are affected.
Andrew MorenoSickle Cell Disease | January 23, 2025
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Melissa BadamoITP | January 23, 2025
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
Belinda Avalos, MDHematology | January 23, 2025
ASH's efforts pertain to professional recruitment as well as to address unique medical issues in patient populations.
Amanda Hess, MBAHematology | January 20, 2025
Clinicians have an important role in helping donation centers make the most of exciting advances and meet recent challenges.
Melissa BadamoHematology | January 17, 2025
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
Andrew MorenoHematology | January 17, 2025
Approval was based on data from the AGAVE-201 trial and is for use in adult and pediatric patients who weigh at least 40 kg.
Melissa BadamoHematology | January 17, 2025
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
Andrew MorenoASH 2024 | January 16, 2025
In a study SCT appeared linked to an increased risk of pregnancy-associated VTE, pulmonary embolism, and isolated DVT.
Melissa BadamoSickle Cell Disease | January 16, 2025
Patients receiving mitapivat showed a statistically significant hemoglobin response rate compared with placebo.
Andrew MorenoAnemia | January 15, 2025
Study data show the VAS-101 gel formulation helps preserve therapeutic efficacy and extend useful longevity of stored RBCs.
Advertisement
Advertisement
Advertisement
Latest News

February 8, 2025